China

Category

Beijing University Team Potent Convalescent Plasma-based Antibody Ready for Clinical Trials: Could Reduce COVID-19 Recovery Time

A Beijing University research team working “day and night” claims to have successfully tested a drug that could shorten the recovery time for patients infected with SARS-CoV-2, the virus behind the COVID-19 pandemic, hence offering a more near-term approach to...

Can Recombinant Human Interferon Alpha-1b Nasal Drops Protect Medical Staff from COVID-19?

Shanghai Jiao Tong University School of Medicine recently concluded an open label, prospective, non-randomized and interventional Phase III study investigating the preventive effect of recombinant human interferon alpha nasal drops on the infection rates of COVID-19...

Guangzhou Sun Yat-sen University Embraces Secarna Pharmaceuticals’ ‘Next Generation’ Antisense Oligonucleotide Platform for COVID-19

A Munich-based biotech venture called Secarna Pharmaceuticals GmbH & Co. KG (“Secarna”) focusing on the discovery and development of next generation antisense oligonucleotide (ASO) therapies to address challenging or previously undruggable targets via its LNAPlus™...

Pin It on Pinterest